KRASG12D mutant cells, pancreatic cell, and Wnt5a signaling

KRASG12D mutant cells are a type of genetically altered pancreatic cells that play a key role in pancreatic cancer development, specifically pancreatic ductal adenocarcinoma (PDAC). Normally, the pancreas has protective mechanisms to eliminate mutant cells to maintain healthy tissue and prevent cancer. However, KRASG12D mutant cells manage to bypass these natural elimination systems and persist in the pancreas.

The study found that Wnt5a signaling is crucial for helping KRASG12D mutant cells survive. Wnt5a is part of the noncanonical Wnt signaling pathway, which is different from the β-catenin-dependent pathway. In KRASG12D mutant cells, Wnt5a signaling stabilizes cell junctions by increasing E-cadherin and β-catenin levels, making the cells stick together more tightly. This prevents their expulsion from the pancreatic tissue. Additionally, Wnt5a suppresses E-cadherin internalization, reducing the cells' motility and anchoring them in place.

KRASG12D cells also enter a state of dormancy, where they stop dividing but remain alive. This dormancy is marked by high levels of proteins like p27 and Sox9, which protect the cells from immune clearance and apoptosis (cell death). Dormancy allows these mutant cells to survive long-term and gain stem-like properties, increasing their tumor-initiating potential.

When KRASG12D is combined with another mutation, p53R172H, the elimination of mutant cells is completely blocked, leading to preneoplastic lesions and tumors. Targeting Wnt5a signaling or reversing dormancy could potentially prevent these mutant cells from surviving and progressing into cancer, offering new therapeutic strategies for pancreatic cancer.